Addition of Pepscan with its peptide discovery, lead optimization and GMP manufacturing capabilities provides end-to-end offering to Biosynth Carbosynth’s peptide customers.
The 41,000 sq ft facility will be utilized to manufacture clinical to commercial-grade peptide products for increased manufacturing capacity
Agreement to co-develop artificial intelligence (AI) technology for the application in peptide drug design
The investigational compound, GZR18, is a novel analogue of glucagon-like peptide-1 (GLP-1), an incretin hormone responsible for many glucoregulatory effects
ICICI Securities expects Hemmo to grow its revenue at a CAGR of 30.0% over FY21E-FY23E
The new facility will enhance AbbVie’s chemical synthesis capacity to support domestic production of current and next-generation neuroscience, immunology, and oncology medicines
Reported EBITDA up by 19% year-on-year with reported EBITDA margin at 25%
Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US
The Swiss peptide and oligonucleotide manufacturers roll out major investments across site networks in US, UK and Switzerland
Subscribe To Our Newsletter & Stay Updated
